Arcturus Therapeutics

Showing 2 posts of 2 posts found.

Arcturus Therapeutics provides update on OTC deficiency and CF programmes

July 2, 2024
Research and Development Arcturus Therapeutics, OTC, Pharmacy, clinical trials, cystic fibrosis

Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, …

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023
Research and Development Arcturus Therapeutics, Chronic Diseases, FDA, ODD, cystic fibrosis

Arcturus Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARCT-032, …

The Gateway to Local Adoption Series

Latest content